[Clinical value of thrombocyte aggregation inhibitors during massive-dose estrogen therapy].

Abstract

Due to an advanced prostatic carcinoma 166 patients were given a massive dose of oestrogen over a period of 10 days (6 g Honvan i.v.). A retrospective comparison of a control group of 94 patients without prophylaxis against thrombosis and a control group of 36 patients having received Heparin-Dihydergot did not show a significant difference of cardiovascular complications. Therefore, further 36 patients received a thrombocyte aggregation inhibitor (Godamed) as prophylaxis against embolic thrombosis. At the same time lung perfusion scintigraphy (99m Tc-Microspheres) was made directly before and after oestrogen therapy. Clinically and lung scintigraphically there was no different thromboembolic incidence compared to the patients given a Heparin-Dihydergot prophylaxis.

• Authors: A Heinz, W W Meyer, O Hallwachs
• Journal: Der Urologe. Ausg. A (Urologe A) Vol. 23 Issue 3 Pg. 178-80 (May 1984) ISSN: 0340-2592 [Print] Germany
• Vernacular Title: Klinische Wertigkeit von Thrombozytenaggregationshemmern bei Ostrogen-Stoss-Therapie.
• PMID: 6377650 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)

Chemical References

• Anticoagulants
• Antineoplastic Agents
• Drug Combinations
• Heparin, Low-Molecular-Weight
• godamed
• heparin-dihydergot
• Dihydroergotamine
• Diethylstilbestrol
• Heparin
• fosfestrol
• Aspirin
• Glycine

Topics

• Aged
• Anticoagulants (pharmacology, therapeutic use)
• Antineoplastic Agents (administration & dosage)
• Aspirin (pharmacology, therapeutic use)
• Clinical Trials as Topic
• Diethylstilbestrol (administration & dosage, adverse effects, analogs & derivatives)
• Dihydroergotamine (pharmacology)
• Drug Combinations (pharmacology, therapeutic use)
• Glycine (pharmacology, therapeutic use)
• Heparin (pharmacology)
• Heparin, Low-Molecular-Weight
• Humans
• Male
• Platelet Aggregation (drug effects)
• Prostatic Neoplasms (drug therapy)
• Retrospective Studies
• Thromboembolism (prevention & control)